BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Acetylon Pharmaceuticals 



Boston  Massachusetts    U.S.A.
Phone: 617-435-2664 Fax: n/a


SEARCH JOBS




Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Acetylon Pharmaceuticals Presents Positive Preclinical Data On Selective HDAC1/2 Inhibition For The Treatment Of Sickle Cell Disease/?-Thalassemia 12/9/2014 1:48:47 PM
Acetylon Pharmaceuticals Announces Ricolinostat Continues To Demonstrate Clinically Meaningful And Durable Disease Response Rates In Phase 1b Combination Studies In Multiple Myeloma 12/9/2014 11:12:07 AM
Acetylon Pharmaceuticals Initiates Phase 2 Study Of Ricolinostat (ACY-1215) In Combination With Pomalyst® 12/4/2014 9:34:25 AM
Acetylon Pharmaceuticals’s Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th American Society of Hematology Annual Meeting And Exposition 12/1/2014 2:45:37 PM
Acetylon Pharmaceuticals Reports Ricolinostat (ACY-1215) Is Active And Well-Tolerated In Ongoing Phase 1b Studies In Patients With Refractory Multiple Myeloma At The 19th Congress Of The European Hematology Association 6/13/2014 12:02:38 PM
Acetylon Pharmaceuticals Celebrates Headquarters Expansion In Boston’s Innovation District 3/20/2014 10:09:04 AM
Acetylon Pharmaceuticals Presents Data On The Potent Activity Of Ricolinostat (ACY-1215) In Preclinical Models Of Lymphoma At The American Society of Hematology Annual Meeting 12/10/2013 12:04:01 PM
Acetylon Pharmaceuticals Highlights Positive Interim Phase 1b Clinical Data Of Ricolinostat (ACY-1215) In Multiple Myeloma At American Society of Hematology Annual Meeting 12/10/2013 10:18:15 AM
Acetylon Pharmaceuticals Presents Preclinical Data for Selective HDAC1/2 Inhibitors For The Treatment Of Sickle Cell Disease And ß-Thalassemia At The American Society of Hematology Annual Meeting 12/10/2013 6:51:51 AM
Acetylon Pharmaceuticals’ Selective Hdac Inhibitors In Multiple Myeloma, Lymphoma And Sickle Cell Disease And ?-Thalassemia To Be Featured In 11 Presentations At American Society of Hematology Annual Meeting 11/25/2013 8:51:15 AM
1234